Although consensus on the optimal criteria for LT patient selection in HCC is yet to be reached, the likely direction is that the tumor burden limit will be expanded and that a composite criterion will be implemented, where markers beyond tumor size, such as AFP, will be considered. This evidence concerns the gene AFP and neoplasm.